Expertise

·         Prenatal examinations and delivery

·         Fetal ultrasound (High-level ultrasound, preeclampsia screening)

·         Gynecological laparoscopic minimally invasive surgery

·         Hysteroscopy and hysteroscopic surgery (including cold knife polyp removal)

·         Menstrual abnormalities and hormonal regulation

·         Pap smears/cervical biopsies, HPV testing, and vaccination

 

1. Historical Context: From 2002 to 2026

Menopausal Hormone Therapy (MHT) experienced a major turning point in medical history. The 2002 U.S. Women's Health Initiative (WHI) report suggested that hormone use might increase the risk of breast cancer, cardiovascular disease, and stroke, leading to 20 years of clinical caution.

Scientific Re-evaluation

·         Limitations of the WHI Study: Participants had an average age over 63 and had mostly been menopausal for more than 10 years.

·         Modern Standards: The drug formulations used in 2002 differ significantly from current clinical standards.

·         2026 Consensus: International medical communities now agree that for women under 60 or within 10 years of menopause, the benefits of starting MHT during the "Golden Window" generally outweigh the risks.

 

2. Core Mechanism of MHT

Estrogen receptors are widely distributed in the brain, cardiovascular system, bones, and urogenital tract. As ovarian function declines, the drop in hormones leaves these systems unprotected, accelerating aging. Modern medicine positions MHT as a strategy focused on symptom relief with secondary preventive benefits.

 

3. Four Major Health Benefits

1. Effective Symptom Relief

MHT is the most effective treatment for vasomotor symptoms like hot flashes and night sweats, reducing frequency by approximately 75%. It also significantly improves urogenital atrophy, such as dryness and frequent urination.

2. Prevention of Osteoporosis and Fractures

Estrogen inhibits bone loss and maintains density. Large-scale trials show that MHT reduces the risk of hip fractures by 34% and overall fracture risk by 24%.

3. Cardiovascular Protection and Reduced Mortality

According to the "Timing Hypothesis," using MHT early in menopause—before significant arterial hardening—promotes vasodilation and inhibits atherosclerosis. Appropriate timing can reduce all-cause mortality by approximately 30% and cardiovascular death risk by nearly half.

4. Metabolic Improvement

Declining hormones after menopause increase visceral fat and insulin resistance. Meta-analyses indicate that MHT can reduce the incidence of Type 2 Diabetes by about 30% and improve various metabolic indicators.

 

4. Addressing Misunderstood Risks

Breast Cancer Risk

·         Formulation Matters: The relationship between MHT and breast cancer depends heavily on the drug combination.

·         Estrogen Alone: Long-term follow-up for women with prior hysterectomies shows no increased risk, with some analyses even showing a slight decrease.

·         Progesterone Selection: Natural micronized progesterone (structurally identical to human secretions) has a neutral effect on breast tissue, offering a significantly better risk profile than traditional synthetic progestins like MPA.

Blood Clot (Thrombosis) Risk

·         Oral vs. Transdermal: Oral estrogen can stimulate clotting factors due to the liver's first-pass effect, doubling the risk of venous thromboembolism (VTE).

·         Preferential Delivery: Transdermal routes (patches or gels) bypass liver metabolism. Large studies show their VTE risk is not significantly different from non-users, making them the preferred choice for women with obesity or hypertension.

 

5. The "Golden Window" Strategy for 2026

Modern medical decisions emphasize "how to use safely" through individualized clinical assessment:

·         Timing: Initiation should ideally occur before age 60 or within 10 years of menopause onset.

·         Administration: Priority is given to transdermal formulations for high-risk profiles.

·         Progesterone Choice: Natural micronized types are preferred over synthetic options.

·         Dosage: Use the lowest effective dose to achieve clinical goals.

·         Contraindications: Careful screening is required for those with a history of breast cancer, blood clots, or liver disease.

 

Important Reminder on Timing of Use

The U.S. Preventive Services Task Force (USPSTF) recommends that MHT should not be used for the prevention of chronic conditions (such as cardiovascular disease or dementia) in "asymptomatic women". For women experiencing natural menopause, MHT should only be initiated under the premise that there are symptoms requiring treatment. By starting therapy within the "Golden Window," patients can achieve both symptom relief and long-term health benefits simultaneously.

 

6. Conclusion: From Fear to Precision Medicine

The evolution of MHT from the 2002 panic to 2026 precision reflects the continuous refinement of medical science. When applied at the right time, for the right population, and with the appropriate dosage and delivery method, MHT is a vital tool for maintaining quality of life and long-term health.